NovoCure (NASDAQ:NVCR) Raised to “Buy” at Wall Street Zen

NovoCure (NASDAQ:NVCR) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other research firms have also commented on NVCR. HC Wainwright set a $32.00 price objective on shares of NovoCure in a research note on Friday, July 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NovoCure in a research report on Thursday, August 27th. Zacks Research upgraded shares of NovoCure from a “strong sell” rating to a “hold” rating in a report on Friday, July 24th. Wells Fargo & Company lowered their price objective on shares of NovoCure from $20.00 to $15.00 and set an “equal weight” rating for the company in a research note on Friday. Finally, Wedbush increased their price objective on shares of NovoCure from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $20.80.

NovoCure Price Performance

Shares of NASDAQ:NVCR opened at $13.15 on Friday. The business has a 50-day simple moving average of $15.79 and a two-hundred day simple moving average of $14.79. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -12.41 and a beta of 1.09. NovoCure has a fifty-two week low of $9.82 and a fifty-two week high of $21.45. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.34 and a current ratio of 2.49.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings data on Thursday, October 29th. The medical equipment provider reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.14. The firm had revenue of $193.40 million during the quarter, compared to analysts’ expectations of $182.28 million. NovoCure had a negative return on equity of 35.81% and a negative net margin of 16.78%. The business’s quarterly revenue was up 15.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.33) EPS. On average, analysts expect that NovoCure will post -1.20 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NVCR. Elevation Wealth Partners LLC increased its holdings in NovoCure by 196.4% during the third quarter. Elevation Wealth Partners LLC now owns 1,731 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 1,147 shares during the last quarter. First Bancorp Inc ME purchased a new stake in shares of NovoCure during the 2nd quarter valued at about $38,000. Allworth Financial LP increased its holdings in NovoCure by 182.0% during the second quarter. Allworth Financial LP now owns 2,721 shares of the medical equipment provider’s stock valued at $41,000 after buying an additional 1,756 shares during the period. Sterling Capital Management LLC lifted its holdings in NovoCure by 591.6% in the third quarter. Sterling Capital Management LLC now owns 3,458 shares of the medical equipment provider’s stock valued at $55,000 after acquiring an additional 2,958 shares during the period. Finally, Integrated Wealth Concepts LLC acquired a new position in NovoCure in the second quarter valued at approximately $84,000. 84.61% of the stock is currently owned by institutional investors.

Key Stories Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported third-quarter revenue of $193.4 million, up 15.7% year over year and above the $182.3 million analyst consensus. Its adjusted loss of $0.09 per share was substantially narrower than the expected $0.23 loss and the year-ago loss of $0.33. NovoCure Shares Fall After Narrower Q3 Loss, Revenue Beat
• Positive Sentiment: Management raised its 2026 guidance, reinforcing expectations for continued revenue growth and improved financial performance. The earnings call also provided additional detail on the company’s commercial and clinical strategy. NovoCure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
• Positive Sentiment: NovoCure entered a clinical-trial collaboration and supply agreement with Verastem Oncology to evaluate Tumor Treating Fields therapy alongside VS-7375 for pancreatic cancer. The partnership could expand the company’s pipeline and future indications. NovoCure and Verastem Collaboration
• Neutral Sentiment: Despite the earnings beat, NovoCure remains unprofitable, with a negative net margin and return on equity. Investors therefore remain focused on whether higher revenue and raised guidance can translate into sustainable profitability. NovoCure Third-Quarter Results
• Negative Sentiment: NovoCure’s CEO said adoption of the Optune Pax system was slowed by competition from Revolution Medicines’ daraxonrasib. Wedbush characterized the issue as a disruption rather than direct competition, but the slower adoption raises concerns about near-term commercial momentum. Optune Pax Adoption Commentary
• Negative Sentiment: Wells Fargo lowered its price target for NVCR from $20 to $15 and maintained an “equal weight” rating. Although the new target implies upside, the sharp reduction signals reduced confidence in the stock’s near-term risk-reward profile. Wells Fargo NovoCure Rating

About NovoCure

NovoCure Ltd. (NASDAQ: NVCR) is an oncology company that develops and commercializes therapies based on Tumor Treating Fields (TTFields), low-intensity electric fields designed to disrupt the division of cancer cells. Its treatments are delivered through portable, wearable devices used alongside other cancer therapies.

The company’s principal products include Optune Gio for certain adults with glioblastoma and Optune Lua for adults with unresectable, locally advanced or metastatic pleural mesothelioma and certain forms of metastatic non-small cell lung cancer.